Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 1 | EJNMMI Radiopharmacy and Chemistry

Fig. 1

From: Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer

Fig. 1

A SDS-PAGE analysis of trastuzumab under non-reducing conditions (lane 1) or reducing conditions (DTT, lane 2) on a 4–20% Tris HCl gradient mini-gel. MW: broad range molecular weight standards. The gel was stained with Coomassie R-250 Brilliant Blue. B Corresponding Western blot under non-reducing (lane 1) or reducing (lane 2) conditions showing immunopositivity with goat anti-human Fab specific IgG-horseradish peroxidase (HRP) immunoconjugates. Bands were detected by reaction with diamidobenzidine/0.03% H2O2. C SE-HPLC analysis of trastuzumab on a BioSep SEC-s4000 column (Phenomenex, Torrance, CA, USA) eluted with 100 mM NaH2PO4 buffer, pH 7.0 at a flow rate of 0.8 mL/min with UV detection at 280 nm

Back to article page